Martin Knapp1, Valentina Iemmi, Renee Romeo. 1. Centre for the Economics of Mental Health, Institute of Psychiatry at King's College London, London, UK. m.knapp@lse.ac.uk
Abstract
OBJECTIVE: We reviewed evidence on the cost-effectiveness of prevention, care and treatment strategies in relation to dementia. METHODS: We performed a systematic review of available literature on economic evaluations of dementia care, searching key databases and websites in medicine, social care and economics. Literature reviews were privileged, and other study designs were included only to fill gaps in the evidence base. Narrative analysis was used to synthesise the results. RESULTS: We identified 56 literature reviews and 29 single studies offering economic evidence on dementia care. There is more cost-effectiveness evidence on pharmacological therapies than other interventions. Acetylcholinesterase inhibitors for mild-to-moderate disease and memantine for moderate-to-severe disease were found to be cost-effective. Regarding non-pharmacological treatments, cognitive stimulation therapy, tailored activity programme and occupational therapy were found to be more cost-effective than usual care. There was some evidence to suggest that respite care in day settings and psychosocial interventions for carers could be cost-effective. Coordinated care management and personal budgets held by carers have also demonstrated cost-effectiveness in some studies. CONCLUSION: Five barriers to achieving better value for money in dementia care were identified: the scarcity and low methodological quality of available studies, the difficulty of generalising from available evidence, the narrowness of cost measures, a reluctance to implement evidence and the poor coordination of health and social care provision and financing.
OBJECTIVE: We reviewed evidence on the cost-effectiveness of prevention, care and treatment strategies in relation to dementia. METHODS: We performed a systematic review of available literature on economic evaluations of dementia care, searching key databases and websites in medicine, social care and economics. Literature reviews were privileged, and other study designs were included only to fill gaps in the evidence base. Narrative analysis was used to synthesise the results. RESULTS: We identified 56 literature reviews and 29 single studies offering economic evidence on dementia care. There is more cost-effectiveness evidence on pharmacological therapies than other interventions. Acetylcholinesterase inhibitors for mild-to-moderate disease and memantine for moderate-to-severe disease were found to be cost-effective. Regarding non-pharmacological treatments, cognitive stimulation therapy, tailored activity programme and occupational therapy were found to be more cost-effective than usual care. There was some evidence to suggest that respite care in day settings and psychosocial interventions for carers could be cost-effective. Coordinated care management and personal budgets held by carers have also demonstrated cost-effectiveness in some studies. CONCLUSION: Five barriers to achieving better value for money in dementia care were identified: the scarcity and low methodological quality of available studies, the difficulty of generalising from available evidence, the narrowness of cost measures, a reluctance to implement evidence and the poor coordination of health and social care provision and financing.
Authors: Robert O Morgan; David M Bass; Katherine S Judge; C F Liu; Nancy Wilson; A Lynn Snow; Paul Pirraglia; Maurilio Garcia-Maldonado; Paul Raia; N N Fouladi; Mark E Kunik Journal: J Gen Intern Med Date: 2015-02-10 Impact factor: 5.128
Authors: Nicholas T Bott; Clifford C Sheckter; Daniel Yang; Stephanie Peters; Brian Brady; Scooter Plowman; Soo Borson; Bruce Leff; Robert M Kaplan; Terry Platchek; Arnold Milstein Journal: Am J Geriatr Psychiatry Date: 2018-09-28 Impact factor: 4.105
Authors: Quincy M Samus; Deirdre Johnston; Betty S Black; Edward Hess; Christopher Lyman; Amrita Vavilikolanu; Jane Pollutra; Jeannie-Marie Leoutsakos; Laura N Gitlin; Peter V Rabins; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2014-01-04 Impact factor: 4.105
Authors: Colleen J Maxwell; Mary Vu; David B Hogan; Scott B Patten; Micaela Jantzi; Marie-Jeanne Kergoat; Nathalie Jetté; Susan E Bronskill; George Heckman; John P Hirdes Journal: Drugs Aging Date: 2013-07 Impact factor: 3.923
Authors: Zheng Kang Lum; Ma Serrie P Suministrado; N Venketasubramanian; M Kamran Ikram; Christopher Chen Journal: Singapore Med J Date: 2018-06-22 Impact factor: 1.858